Working… Menu

A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04154293
Recruitment Status : Recruiting
First Posted : November 6, 2019
Last Update Posted : January 22, 2021
Information provided by (Responsible Party):
Timber Pharmceuticals LLC

Brief Summary:

The purpose of this study is to investigate the efficacy and safety of two concentrations of topically applied ointment formulation of isotretinoin called TMB-001 (0.05% and 0.1% isotretinoin) in subjects 9 years of age and older for the treatment of congenital ichthyosis (CI), including recessive X-linked ichthyosis (RXLI) and autosomal recessive congenital ichthyosis-lamellar ichthyosis (ARCI-LI) subtypes.

Funding Source FDA-OOPD

Condition or disease Intervention/treatment Phase
Congenital Ichthyosis Drug: Isotretinoin Other: Vehicle Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A Randomized, Parallel, Double-Blind, Vehicle-Controlled Study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blind
Primary Purpose: Treatment
Official Title: A Randomized, Parallel, Double-Blind, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Two Concentrations of Topical TMB-001 for the Treatment of Congenital Ichthyosis
Actual Study Start Date : December 3, 2019
Estimated Primary Completion Date : July 30, 2021
Estimated Study Completion Date : August 30, 2021

Arm Intervention/treatment
Placebo Comparator: Vehicle Ointment (Control)
Topical, BID (Twice daily)
Other: Vehicle
Topical Vehicle Ointment

Experimental: TMB-001 Ointment, 0.05%
Topical, BID ( twice daily)
Drug: Isotretinoin
Topical Isotretinoin ointment

Experimental: TMB-001 Ointment, 0.1%
Topical, BID (Twice daily)
Drug: Isotretinoin
Topical Isotretinoin ointment

Primary Outcome Measures :
  1. Reduction in targeted Ichthyosis severity [ Time Frame: 12 weeks ]
    Proportion of subjects with Visual Index for Ichthyosis Severity (VIIS) treatment success, defined as 50% or greater decreased in VIIS scaling score

Secondary Outcome Measures :
  1. Reduction in overall Ichthyosis severity [ Time Frame: 12 weeks ]
    Investigator Global Assessment decrease in disease severity by at least 2 grades

  2. Patient Reported Outcomes [ Time Frame: 12 weeks ]
    Change in Itch-Numeric Rating Scale

  3. Patient Reported Outcomes [ Time Frame: 12 weeks ]
    Change in Dermatology Life Quality Index

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   9 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is male or female, 9 years of age or older at Visit 2 (Baseline)
  • Subject has provided written informed consent
  • Females of child bearing potential must be surgically sterile or agree to 2 forms of birth control
  • Subject has clinical diagnosis of Congenital Ichthyosis with genetic confirmation of subtype
  • Subject has between 10% and 90% total BSA affected by Congenital Ichthyosis
  • Subject has at least 2 VIIS assessment areas with a scaling score of 3 or greater

Exclusion Criteria:

  • Subject has inflammatory skin diseases unrelated to ichthyosis
  • Subject has used other prohibited topical treatments in the assessment areas within certain days from baseline
  • Subject has used systemic retinoids within12 weeks of baseline
  • Subject has untreated secondary infections
  • Subject has lesions suspicious for skin cancer or untreated skin cancers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04154293

Layout table for location contacts
Contact: Jessica Raiz, MPH +19732149208

Layout table for location information
United States, Arizona
Medical Dermatology Specialists Recruiting
Phoenix, Arizona, United States, 85006
Contact: Katherine Delphin    602-354-5770 ext 38   
United States, California
Stanford University School of Medicine Recruiting
Palo Alto, California, United States, 94304
Contact: Elidia Tafoya    650-721-1227   
United States, Connecticut
Yale Center for Clinical Investigation Recruiting
New Haven, Connecticut, United States, 06510
Contact: Mahin Dawood    203-785-5505   
United States, Indiana
The Indiana Clinical Trials Center Recruiting
Plainfield, Indiana, United States, 46168
Contact: Kacy Parker    317-837-6082   
Contact: Kimmie Eads    317-837-6082   
United States, Louisiana
Austin Institute for Clinical Research, Inc Recruiting
Metairie, Louisiana, United States, 70005
Contact: Michelle Bursavich    504-264-6455   
United States, Minnesota
Minnesota Clinical Study Center Recruiting
New Brighton, Minnesota, United States, 55112
Contact: Allie Horita    763-571-4200   
United States, Ohio
Cincinnati Children's Hospital Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Mary Fisher    352-256-5936   
United States, Pennsylvania
The Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19140
Contact: Jasmine Hanks    215-590-0862   
Contact: Leslie Castelo-Soccio    215-590-0862   
Australia, Queensland
Queensland Children's Hospital Recruiting
Brisbane, Queensland, Australia, 4101
Contact: Amanda James    07 3069 7705   
Australia, Sydney
Premier Specialists, The church Recruiting
Kogarah, Sydney, Australia, NSW 2217
Contact: Helen Dickenson-Panas    +61 02 9598 5800   
Australia, Victoria
Murdoch Children's Research Institute, RCH Recruiting
Melbourne, Victoria, Australia, 3052
Contact: Nicole Davidson    061 3 9936 6144   
Sponsors and Collaborators
Timber Pharmceuticals LLC
Layout table for additonal information
Responsible Party: Timber Pharmceuticals LLC Identifier: NCT04154293    
Other Study ID Numbers: 235-9051-202
1R01FD006079-01A1 ( U.S. FDA Grant/Contract )
First Posted: November 6, 2019    Key Record Dates
Last Update Posted: January 22, 2021
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ichthyosis, Lamellar
Ichthyosiform Erythroderma, Congenital
Skin Abnormalities
Congenital Abnormalities
Infant, Newborn, Diseases
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Dermatologic Agents